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OBJECTIVE — The A1C-Derived Average Glucose study recommended reporting A1C in
estimated average glucose (eAG) equivalents. We compared eAG with self-monitored mean
blood glucose (MBG) to determine whether eAG is systematically biased due to biological
variation in the relationship between MBG and A1C.
RESEARCH DESIGN AND METHODS — MBG and A1C were recorded from charts of
202pediatrictype1diabeticpatientsat1,612clinicvisits.Patientsweredividedintogroupswith
low, moderate, or high A1C bias based on a hemoglobin glycation index (HGI).
RESULTS — The mean  SD values for MBG versus eAG were as follows: total population,
194  34 vs. 196  36 mg/dl; low-HGI group, 186  31 vs. 163  20 mg/dl; moderate-HGI
group, 195  28 vs. 193  19 mg/dl; and high-HGI group, 199  42 vs. 230  31 mg/dl.
CONCLUSIONS — eAG underestimated MBG in low HGI patients and overestimated MBG
in high HGI patients. Disagreement between eAG and MBG downloaded from patient glucose
meters will cause confusion if eAG is implemented for clinical use.
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T
he A1C-Derived Average Glucose
(ADAG) study (1) recommended
translating A1C into estimated aver-
age glucose (eAG) equivalents for moni-
toring glycemic control. Controversy
persists over the underlying assumption
that A1C levels depend exclusively on
long-term previous blood glucose con-
centration (2–6). A number of studies
have shown that biological variation in
A1C is inﬂuenced by factors other than
blood glucose concentration (7–13). This
suggests that eAG may be a systematically
biased estimate of self-monitored mean
blood glucose (MBG).
RESEARCH DESIGN AND
METHODS— This study is an exten-
sion of a report on patients with type 1
diabetes at Children’s Hospital of New
Orleans (14) and was approved by the
Institutional Review Board at Louisiana
State University Health Sciences Center,
New Orleans, Louisiana. Patients at-
tended diabetes clinics approximately ev-
ery3months.Datawerecollectedfroman
average of eight clinic visits per patient.
Glycemic variables
MBG and A1C were transcribed from pa-
tientchartsasenteredbyclinicpersonnel.
Glucose data were downloaded from pa-
tient meters at each clinic visit. Meter
model and sampling protocols varied by
patient preference and insurance pro-
vider. MBG values were calculated over
periods of at least 30 days. An average of
threeglucosemeasurementsperdaywere
recorded in a study using a similar self-
monitoring protocol (7). A1C was mea-
sured by National Glycohemoglobin
Standardization Program (NGSP)-
approved immunoassays (15) at the Chil-
dren’s Hospital (184 patients) or by
commercial laboratories that presumably
also used NGSP-approved methods (18
patients, including 4 low-, 7 moderate-,
and 7 high-HGI subjects).
Hemoglobin glycation index
A population regression equation {A1C
(%)[0.021MBG(mg/dl)]4.3,r
0.57} was derived using mean MBG and
mean A1C from 202 patients collected at
1,612 clinic visits as described elsewhere
(14).Thesamedatawereusedtocalculate
hemoglobin glycation index (HGI) and to
divide patients into low-, moderate-, and
high-HGI groups. Predicted A1C values
were calculated at each clinic visit by in-
sertingMBGintotheregressionequation.
HGI values were calculated by subtract-
ing predicted A1C from observed A1C
measured at the same clinic visit. Patients
were divided into low-, moderate-, and
high-HGIgroupsbasedonmeanHGIter-
tile (33%) rank (low HGI, 0.41, n 
67; moderate HGI, 0.41 to 0.26, n 
68; high HGI, 0.26, n  67).
eAG
eAG was calculated by inserting observed
A1C into the ADAG linear regression
equation (eAG [mg/dl]  [28.7  A1C
(%)]46.7,r0.92)(1).Ameanblood
glucose index (MBGI) that quantiﬁes the
difference between MBG and eAG was
calculated by subtracting observed MBG
from eAG.
Statistical analysis
Descriptivestatisticsandlinearregression
analyses were generated using GraphPad
Prism v. 4.03 (GraphPad Software, San
Diego, CA).
RESULTS— In our original descrip-
tion of this study population (14) we re-
ported that the mean  SD values of
glycemic variables for the low-, moder-
ate-, and high-HGI groups, respectively,
were: MBG, 186  31, 195  28, and
199  42 mg/dl; A1C, 7.6  0.7, 8.4 
0.7, and 9.6  1.1%; and HGI, 1.0 
0.4, 0.1  0.2, and 1.1  0.9%. The
presentanalysisusedA1Cfromthatstudy
to calculate mean eAG for the low, mod-
erate, and high HGI groups, respectively,
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230  31 mg/dl. Figure 1 compares eAG
and MBG in the population and in the
different HGI groups and shows that
mean eAG and mean MBG were similar
when compared in the population or in
the moderate-HGI group. In contrast,
eAG underestimated MBG by an average
of 12% (23 mg/dl) in the low-HGI group
and overestimated MBG by 16% (31 mg/
dl) in the high-HGI group. The average
differencebetweeneAGandMBGinthese
groups represented an A1C difference of
about1%basedontheslopeoftheADAG
regression equation. Linear regression
analysis of HGI versus MBGI for all 202
patients showed that MBGI (the mean
difference between eAG and MBG) for in-
dividual patients was signiﬁcantly posi-
tively correlated with mean HGI {MBGI
(mg/dl)  [28.7  HGI (%)]  1.9, r 
0.91, P  0.0001}.
CONCLUSIONS — TheADAGstudy
concluded that A1C could be reliably
translated into eAG based on the linear
relationship between A1C and mean
blood glucose measured by continuous
glucosemonitoringinamixedpopulation
of diabetic and nondiabetic subjects (1).
This conclusion assumes that all popula-
tion variation in A1C is either random or
due to variation in blood glucose concen-
tration.However,numerousreportsofbi-
ological variation in A1C (7–13) indicate
that this assumption is false. We previ-
ously developed HGI to quantify biologi-
cal variation in A1C due to factors other
than blood glucose concentration and
showed that HGI was quantitatively con-
sistent within individuals over time, dif-
ferent between individuals, normally
distributed and positively correlated with
risk for complications (7,8,14). The fact
that many patients have HGI values that
are always positive or always negative in-
dicates that HGI measures systematic
A1C bias between individuals. The
present study clearly demonstrates that
thissystematicA1CbiasmakeseAGasys-
tematicallybiasedestimateofMBGdown-
loaded from patient glucose meters in
high- and low-HGI patients.
It is important to emphasize that the
presentstudyusedroutineA1CandMBG
data typical of that available in most dia-
betes clinics. If A1C is reported as eAG,
patients and clinicians will be confronted
with signiﬁcant discrepancies between
eAG and self-monitored MBG, which will
confound interpretation of glycemic con-
trol. Furthermore, treating patients based
on eAG alone could result in inappropri-
atemedicaldecisions(2).BasedonFig.1,
if low-HGI patients are intensively man-
aged to a low eAG target, their MBG
would presumably remain above the
target, inadvertently leaving these pa-
tients at unnecessary risk for chronic
complications. Conversely, intensive
management could drive MBG in high-
HGI patients below the eAG target,
which presumably would increase their
risk for hypoglycemia.
We conclude that translating A1C
into eAG produced biased estimates of
MBG downloaded from patient glucose
meters in low- and high-HGI patients.
However, because MBGI (the difference
between eAG and MBG) was positively
correlated with HGI, eAG derived using
the carefully determined ADAG regres-
sion equation may have clinical value for
assessing biological variation in A1C. Ei-
ther HGI or MBGI could prove clinically
useful for more comprehensive risk as-
sessment and personalized patient care.
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